Since l995, I have found many patients, particularly women, respond favorably to dilutions of the hormone Progesterone. Progesterone dilutions have been administered sublingually to thousands of my patients as a routine screening methodology during their initial evaluation.

Over that past 2 years, we made digital video recordings of 350 patients recording their initial evaluation using different dilutions of Progesterone. The symptoms that have been addressed include neck pain, nasal congestion, eye irritation, throat pain, shortness of breath, headache, sinus pressure, ear pain, skin irritation, back pain, hip pain, upper and lower extremity pain. The patients were asked to evaluate their symptoms and place a numerical value on each symptom. They were asked to assess each symptom at the moment of testing on a scale of 0 to 10, with 10 being the worst discomfort of that type they have experienced and 0 being complete absence of symptoms. The numbers below represent the typical relief of symptoms experienced by patients.

Using this methodology, the patients have been given intradermal or sublingual dilutions of Progesterone as set out above. Within a few seconds after the application of the antigens the patients report that they can tell a difference in their symptoms. They report these changes anywhere from 10 to 30 seconds after the antigen is applied. There have been no side effects in any of the tests, nor in any of the patients previously treated with these antigens.

While the digital video recordings are dramatic illustrations of the patients’ perceived response to the antigens, they do not constitute scientific evidence of the effectiveness of the antigen in reducing symptoms nor do they provide scientific evidence of the speed with which the antigens seem to work. In order to demonstrate the effect of the antigen it is necessary to elicit objective scientific evidence of quantifiable changes in the subjects. We began with blood studies. Since 2003, we have been collecting data on Progesterone and Estrogen Antibodies (IgE, IgG and IgM) and have found that over 60% of the patients had out-of-range high levels of these antibodies. Our research paper “Hormone Allergy” was published in the American Journal of Reproductive Immunology March, 2006; 55:307-313.

Hormone antibody levels for IgG and IgM can be ordered from:

Immunosciences Lab., Inc.
8693 Wilshire Blvd.,
Beverly Hills, CA 90211
Website: www.immuno-sci-lab.com

Each patient is given the same sequence of drops. After assessing all the symptoms and assigning a numerical value to each, the placebo drops are placed under the patient’s tongue and they are instructed not to swallow them for a count of five seconds. Then they are asked to swallow the drops. In about five or ten seconds I ask them if they can tell any change in any of their symptoms. One must ask the patient about each area of symptoms. The question is always put to the patient in the same way: “Are your symptoms worse, unchanged, or better?”

This is designed to always give them the option of selecting “worse” or “unchanged” before “better”. The purpose of this is to minimize the power of suggestion or “placebo” effect. The patient is looking to the examiner for clues as to what to expect and we want to minimize the suggestion that their symptoms are expected to get better.

Of course, I frequently see a “placebo effect” that ranges from 10 to 30% relief of symptoms in about 20 to 30% of patients. I think the average placebo effect in our last study was 18% across the board.

If at any point all the symptoms are relieved the tests are concluded and the patient is sent home with the same dilution of progesterone drops that relieved the symptoms. They are instructed to use them as often as they need to as there is no therapeutic amount being delivered. If the symptom relief does not last 12 to 24 hours, they need a vial one dilution stronger.

In summary, the drops are safe. There has never been a serious reaction to a sublingual antigen (WHO). The drops are effective. Over half of presenting symptoms are eliminated in over half of all patients. The relief is fast. It occurs within minutes of the application. The treatment is inexpensive. If we get rid of a patients’ chronic shortness of breath, we stop the ER visits, the hospitalizations, the expensive medical tests and the ineffective inhalers and drugs.

The cost of the drop material is measured in cents, not dollars. The testing and treatment can be performed by entry level technicians. A doctor is only necessary if the drops do not work.

For more information contact:

Russell R. Roby, J.D., M.D., ACAAI, FCLM